This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- CXA-10
- DrugBank Accession Number
- DB15026
- Background
CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for CXA-10 (DB15026)
- Weight
- Average: 327.465
Monoisotopic: 327.240958547 - Chemical Formula
- C18H33NO4
- Synonyms
- 10-nitro-9(E)-octadec-9-enoic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1N19AGY57Y
- CAS number
- 875685-46-4
- InChI Key
- WRADPCFZZWXOTI-BMRADRMJSA-N
- InChI
- InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
- IUPAC Name
- (9E)-10-nitrooctadec-9-enoic acid
- SMILES
- CCCCCCCC\C(=C/CCCCCCCC(O)=O)[N+]([O-])=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0062737
- ChemSpider
- 21375709
- BindingDB
- 50295049
- ChEBI
- 86285
- ChEMBL
- CHEMBL561371
- ZINC
- ZINC000040331256
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Primary Focal Segmental Glomerulosclerosis (FSGS) 1 somestatus stop reason just information to hide 2 Recruiting Treatment Asthma / Obesity 1 somestatus stop reason just information to hide 2 Terminated Treatment Pulmonary Arterial Hypertension (PAH) 3 somestatus stop reason just information to hide 2 Withdrawn Treatment Asthma 1 somestatus stop reason just information to hide 1 Completed Treatment Acute Kidney Injury (AKI) 2 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000774 mg/mL ALOGPS logP 5.26 ALOGPS logP 5.97 Chemaxon logS -5.6 ALOGPS pKa (Strongest Acidic) 4.99 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 80.44 Å2 Chemaxon Rotatable Bond Count 16 Chemaxon Refractivity 92.77 m3·mol-1 Chemaxon Polarizability 39.06 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0006-8290000000-3b45586367964b741ff1 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 215.913996 predictedDarkChem Lite v0.1.0 [M-H]- 190.89299 predictedDeepCCS 1.0 (2019) [M+H]+ 216.226096 predictedDarkChem Lite v0.1.0 [M+H]+ 193.25099 predictedDeepCCS 1.0 (2019) [M+Na]+ 216.646296 predictedDarkChem Lite v0.1.0 [M+Na]+ 199.34413 predictedDeepCCS 1.0 (2019)
Drug created at May 20, 2019 14:43 / Updated at September 12, 2023 18:32